智通财经2月2日讯（编辑 冯轶）智通财经为您带来今日港股重要公告 1）公司要闻 招商局置地(00978.HK)：2025年合同销售总额约为323.08亿元，同比减少23.91%。 环球医疗(02666.HK)：附属拟发行本金总额不超过10亿元公司债。 君圣泰医药-B(02511.HK)：任命Filip Surmont博士为首席医学官，强化心肾代谢系统疾病(CKM)布局。 蓝河控股(00498.HK)：与能储投公司订立合作框架协议。 2）融资、回购动态 钧达股份(02865.HK)：完成配售1868.2万股，净筹约3.98亿港元。 小米集团-W(01810.HK)：斥资2.09亿港元回购600万股，回购价34.54-35.00港元。 中兴通讯(00763.HK)：拟出资1.17亿元认购建兴湛卢基金份额，可投资扶持更大范围的创新业务及上下游产业链企业。 云工场(02512.HK)：附属中标人工智能产业基地二期项目，合约价值为人民币5.2亿元。 小鹏汽车-W(09868.HK)：1月共交付新车20011辆。 拉近网娱(08172.HK)：附属拉近众博获蚂蚁云通授权为"蚂蚁百宝箱官方合作服务商"。 骏东控股(0827 ...

格隆汇2月2日丨君圣泰医药-B(02511.HK)宣布，任命Filip Surmont博士为首席医学官，全面负责公司的 医学战略、临床开发及相关医学事务，助力公司核心管线在心肾代谢系统疾病(CKM)领域的研发进展与 价值提升。 ...

智通财经APP讯，君圣泰医药-B(02511)发布公告，任命Filip Surmont博士为首席医学官，全面负责公司 的医学战略、临床开发及相关医学事务，助力公司核心管线在心肾代谢系统疾病(CKM)领域的研发进展 与价值提升。 ...

君圣泰医药-B(02511)发布公告，任命Filip Surmont博士为首席医学官，全面负责公司的医学战略、临床 开发及相关医学事务，助力公司核心管线在心肾代谢系统疾病(CKM)领域的研发进展与价值提升。 ...

Core Viewpoint - The company reported a significant reduction in losses for the first half of 2025, with a loss of RMB 113.9 million compared to RMB 210.9 million in the same period of 2024, indicating improved financial performance [1] Group 1: Financial Performance - The company recorded a loss of RMB 113.9 million in the first half of 2025, a substantial decrease from the loss of RMB 210.9 million in the first half of 2024 [1] Group 2: Product Pipeline and Innovation - The company is focusing on the potential of its core product HTD1801, which is being developed globally for treating chronic kidney and metabolic diseases, including Type 2 diabetes, metabolic-associated fatty liver disease, chronic kidney disease, obesity, primary sclerosing cholangitis, and severe hypertriglyceridemia [1] - HTD1801 is a novel molecular entity targeting the gut-liver system, acting as an oral anti-inflammatory and metabolic modulator through a dual mechanism of activating AMPK and inhibiting the NLRP3 inflammasome [2] - The company has developed a strong pipeline of innovative drug candidates, including HTD4010, HTF1037, HTF1057, HTD1804, HTD1805, and HTD2802, targeting ten potential indications [1][2] Group 3: Market Opportunity and Demand - The treatment market for chronic kidney and metabolic diseases (CKM) is substantial, affecting nearly 90% of adults in the U.S. and 80% in China, with approximately 590 million diabetes patients globally, indicating a significant unmet need for innovative therapies [3] - HTD1801's dual mechanism shows exceptional therapeutic potential in addressing CKM-related diseases, with clinical studies confirming its multiple benefits in metabolism, kidney function, obesity, and cardiovascular complications [3] Group 4: Intellectual Property and Commercialization Strategy - The company maintains a robust intellectual property portfolio with over 100 patents and applications globally, providing effective market access barriers and supporting its commercialization goals [4] - As HTD1801 approaches commercialization in 2025, the company aims to capitalize on market opportunities and expand its market presence [4]